About Dynein axonemal assembly factor 11
Dynein axonemal assembly factor 11 (DNAAF11) is a protein
from Homo sapiens identified by UniProt accession
Q86X45, 466 residues long.
MolForge cross-references it against 0 known binders and
44 disease associations.
Target properties
| Protein name | Dynein axonemal assembly factor 11 |
| UniProt accession | Q86X45 |
| Gene | DNAAF11 |
| Organism | Homo sapiens |
| Length | 466 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (44)
Diseases linked to this target (Open Targets).
- primary ciliary dyskinesia · score 0.73
- Heterotaxy · score 0.33
- cognitive function measurement · score 0.31
- adolescent idiopathic scoliosis · score 0.30
- smoking status measurement · score 0.15
- smoking initiation · score 0.15
- self reported educational attainment · score 0.14
- infertility · score 0.11
- hypothyroidism · score 0.07
- appendicular lean mass · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86X45-F1 | alphafold | PREDICTED | 74.33 | — |
Amino-acid sequence (466 residues)
MGWITEDLIR RNAEHNDCVI FSLEELSLHQ QEIERLEHID KWCRDLKILY LQNNLIGKIE NVSKLKKLEY LNLALNNIEK IENLEGCEEL AKLDLTVNFI GELSSIKNLQ HNIHLKELFL MGNPCASFDH YREFVVATLP QLKWLDGKEI EPSERIKALQ DYSVIEPQIR EQEKDHCLKR AKLKEEAQRK HQEEDKNEDK RSNAGFDGRW YTDINATLSS LESKDHLQAP DTEEHNTKKL DNSEDDLEFW NKPCLFTPES RLETLRHMEK QRKKQEKLSE KKKKVKPPRT LITEDGKALN VNEPKIDFSL KDNEKQIILD LAVYRYMDTS LIDVDVQPTY VRVMIKGKPF QLVLPAEVKP DSSSAKRSQT TGHLVICMPK VGEVITGGQR AFKSMKTTSD RSREQTNTRS KHMEKLEVDP SKHSFPDVTN IVQEKKHTPR RRPEPKIIPS EEDPTFEDNP EVPPLI
Explore Dynein axonemal assembly factor 11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets